734 related articles for article (PubMed ID: 16170080)
21. The beneficial effects of vitamin D3 on reducing antibody titers against Epstein-Barr virus in multiple sclerosis patients.
Najafipoor A; Roghanian R; Zarkesh-Esfahani SH; Bouzari M; Etemadifar M
Cell Immunol; 2015 Mar; 294(1):9-12. PubMed ID: 25666504
[TBL] [Abstract][Full Text] [Related]
22. Epstein-Barr virus-specific antibodies in Epstein-Barr virus-positive and -negative gastric carcinoma cases in Japan.
Shinkura R; Yamamoto N; Koriyama C; Shinmura Y; Eizuru Y; Tokunaga M
J Med Virol; 2000 Apr; 60(4):411-6. PubMed ID: 10686024
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of the abbot Architect(™) epstein-barr virus viral capsid antigen IgM, viral capsid antigen IgG and nuclear antigen IgG assays in a pediatric and adult population.
Grandjean Lapierre S; Vallières E; Rabaamad L; Labrecque M; Chartrand C; Renaud C
J Clin Virol; 2016 Aug; 81():1-5. PubMed ID: 27258036
[TBL] [Abstract][Full Text] [Related]
24. [Performance of the VIDAS automated immunoassay for the determination of Epstein-Barr virus serological status].
De Ory F; Guisasola ME; Sanz JC; García-Bermejo I
Enferm Infecc Microbiol Clin; 2012 Dec; 30(10):618-20. PubMed ID: 22854635
[TBL] [Abstract][Full Text] [Related]
25. Heightened Epstein-Barr virus immunity and potential cross-reactivities in multiple sclerosis.
Thomas OG; Haigh TA; Croom-Carter D; Leese A; Van Wijck Y; Douglas MR; Rickinson A; Brooks JM; Taylor GS
PLoS Pathog; 2024 Jun; 20(6):e1012177. PubMed ID: 38843296
[TBL] [Abstract][Full Text] [Related]
26. Epstein-Barr virus persistence and reactivation in neuromyelitis optica.
Masuda S; Mori M; Arai K; Uzawa A; Muto M; Uchida T; Masuda H; Kuwabara S
J Neurol Neurosurg Psychiatry; 2015 Oct; 86(10):1137-42. PubMed ID: 25433035
[TBL] [Abstract][Full Text] [Related]
27. Aberrant Epstein-Barr virus persistence in HIV carriers is characterized by anti-Epstein-Barr virus IgA and high cellular viral loads with restricted transcription.
Stevens SJ; Smits PH; Verkuijlen SA; Rockx DA; van Gorp EC; Mulder JW; Middeldorp JM
AIDS; 2007 Oct; 21(16):2141-9. PubMed ID: 18090040
[TBL] [Abstract][Full Text] [Related]
28. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis.
Jilek S; Schluep M; Meylan P; Vingerhoets F; Guignard L; Monney A; Kleeberg J; Le Goff G; Pantaleo G; Du Pasquier RA
Brain; 2008 Jul; 131(Pt 7):1712-21. PubMed ID: 18550621
[TBL] [Abstract][Full Text] [Related]
29. High prevalence of immunoglobulin A antibody against Epstein-Barr virus capsid antigen in adult patients with lupus with disease flare: case control studies.
Chen CJ; Lin KH; Lin SC; Tsai WC; Yen JH; Chang SJ; Lu SN; Liu HW
J Rheumatol; 2005 Jan; 32(1):44-7. PubMed ID: 15630723
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of variations in levels of Epstein-Barr Virus (EBV) antigen and adaptive immune response during chronic active EBV infection in children.
Xing Y; Song HM; Wei M; Liu Y; Zhang YH; Gao L
J Immunotoxicol; 2013; 10(4):387-92. PubMed ID: 23418935
[TBL] [Abstract][Full Text] [Related]
31. Epstein-Barr virus, cytomegalovirus and BK polyomavirus burden in juvenile systemic lupus erythematosus: correlation with clinical and laboratory indices of disease activity.
Aygun D; Kuskucu MA; Sahin S; Adrovic A; Barut K; Yıldız M; Sharifova S; Midilli K; Cokugras H; Camcıoglu Y; Kasapcopur O
Lupus; 2020 Sep; 29(10):1263-1269. PubMed ID: 32646294
[TBL] [Abstract][Full Text] [Related]
32. Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy.
Rød BE; Wergeland S; Bjørnevik K; Holmøy T; Ulvestad E; Njølstad G; Myhr KM; Torkildsen Ø
Mult Scler Relat Disord; 2023 Nov; 79():105037. PubMed ID: 37804765
[TBL] [Abstract][Full Text] [Related]
33. [A comparison of the detection of IgM antibodies against the viral capsid antigen (VCA) of EBV (Epstein-Barr virus) in various groups of patients, using indirect immunofluorescence, indirect ELISA and reverse ELISA. Study of the diagnostic efficacy of the anti-VCA EBV IgM ELISA-VIDITEST kit].
Pumannová M; Rezbová M; Svecová M; Hrbácková H; Novotná M; Ochotná J; Roubalová K
Klin Mikrobiol Infekc Lek; 2004 Aug; 10(4):186-90. PubMed ID: 15328576
[TBL] [Abstract][Full Text] [Related]
34. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis.
Lünemann JD; Edwards N; Muraro PA; Hayashi S; Cohen JI; Münz C; Martin R
Brain; 2006 Jun; 129(Pt 6):1493-506. PubMed ID: 16569670
[TBL] [Abstract][Full Text] [Related]
35. Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis.
Castellazzi M; Tamborino C; Cani A; Negri E; Baldi E; Seraceni S; Tola MR; Granieri E; Contini C; Fainardi E
Mult Scler; 2010 Jul; 16(7):883-7. PubMed ID: 20483883
[TBL] [Abstract][Full Text] [Related]
36. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis.
Zivadinov R; Weinstock-Guttman B; Zorzon M; Uxa L; Serafin M; Bosco A; Bratina A; Maggiore C; Grop A; Tommasi MA; Srinivasaraghavan B; Ramanathan M
J Neuroimmunol; 2009 Apr; 209(1-2):123-30. PubMed ID: 19232441
[TBL] [Abstract][Full Text] [Related]
37. [Investigation of Epstein-Barr virus and herpes simplex virus markers by serological and molecular methods in patients with rheumatoid arthritis and systemic lupus erythematosus].
Us T; Cetin E; Kaşifoğlu N; Kaşifoğlu T; Akgün Y
Mikrobiyol Bul; 2011 Oct; 45(4):677-83. PubMed ID: 22090298
[TBL] [Abstract][Full Text] [Related]
38. Recombinant Epstein-Barr virus glycoprotein 350 as a serological antigen.
Persson Berg L; Thomsson E; Hasi G; Bäckström M; Bergström T
J Virol Methods; 2020 Oct; 284():113927. PubMed ID: 32650039
[TBL] [Abstract][Full Text] [Related]
39. [Systemic lupus erythematosus and Epstein-Barr virus].
Tazi I; Fehri S; Elghrari K; Ouazzani T; Benchemsi N
East Mediterr Health J; 2009; 15(3):701-8. PubMed ID: 19731786
[TBL] [Abstract][Full Text] [Related]
40. Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment.
Castellazzi M; Delbue S; Elia F; Gastaldi M; Franciotta D; Rizzo R; Bellini T; Bergamaschi R; Granieri E; Fainardi E
Dis Markers; 2015; 2015():901312. PubMed ID: 26101453
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
